Ask AI

Immunotherapy

Michael B. Atkins MD and Antoni Ribas MD PhD review data from key presentations on immunotherapy from the 2015 clinical oncology meeting in Chicago.

Share

Program Content

Activities

  • Nivolumab ± Ipilimumab in SCLC
    CheckMate 032: Nivolumab ± Ipilimumab With Promising Activity in Recurrent SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation